drugset / Trial / NCT05024097
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Phase 2
Recruiting
43 enrolled
Weill Medical College of Cornell University
Arcus Biosciences, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
Timeline
- Start
- 2022-03-31
- Primary completion
- 2026-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etrumadenant | Small molecule | 150 mg | Oral |
| Subject | Zimberelimab | Monoclonal antibody | — | — |